JP6373252B2 - オーロラキナーゼ阻害薬を使用する癌の治療方法 - Google Patents

オーロラキナーゼ阻害薬を使用する癌の治療方法 Download PDF

Info

Publication number
JP6373252B2
JP6373252B2 JP2015501852A JP2015501852A JP6373252B2 JP 6373252 B2 JP6373252 B2 JP 6373252B2 JP 2015501852 A JP2015501852 A JP 2015501852A JP 2015501852 A JP2015501852 A JP 2015501852A JP 6373252 B2 JP6373252 B2 JP 6373252B2
Authority
JP
Japan
Prior art keywords
aurora
cancer
paclitaxel
kinase
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015501852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015510945A (ja
JP2015510945A5 (OSRAM
Inventor
アリジット チャクラバーティ，
アリジット チャクラバーティ，
ジェフリー エー． エクセディ，
ジェフリー エー． エクセディ，
ロバート ダブリュー． クレインフィールド，
ロバート ダブリュー． クレインフィールド，
カー エヌ． リ，
カー エヌ． リ，
ウェン チー シュー，
ウェン チー シュー，
カルシク ベンカタクリシュナン，
カルシク ベンカタクリシュナン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2015510945A publication Critical patent/JP2015510945A/ja
Publication of JP2015510945A5 publication Critical patent/JP2015510945A5/ja
Application granted granted Critical
Publication of JP6373252B2 publication Critical patent/JP6373252B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015501852A 2012-03-20 2013-03-19 オーロラキナーゼ阻害薬を使用する癌の治療方法 Active JP6373252B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613258P 2012-03-20 2012-03-20
US61/613,258 2012-03-20
PCT/US2013/032962 WO2013142491A1 (en) 2012-03-20 2013-03-19 Methods of treating cancer using aurora kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2015510945A JP2015510945A (ja) 2015-04-13
JP2015510945A5 JP2015510945A5 (OSRAM) 2016-05-12
JP6373252B2 true JP6373252B2 (ja) 2018-08-15

Family

ID=48048255

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015501852A Active JP6373252B2 (ja) 2012-03-20 2013-03-19 オーロラキナーゼ阻害薬を使用する癌の治療方法

Country Status (24)

Country Link
US (2) US20130303519A1 (OSRAM)
EP (1) EP2827855B1 (OSRAM)
JP (1) JP6373252B2 (OSRAM)
KR (1) KR102128866B1 (OSRAM)
CN (1) CN104271129A (OSRAM)
AU (1) AU2013235275B2 (OSRAM)
CA (1) CA2868024A1 (OSRAM)
EA (1) EA036434B1 (OSRAM)
ES (1) ES2746946T3 (OSRAM)
GE (1) GEP20186900B (OSRAM)
IL (1) IL234686B (OSRAM)
IN (1) IN2014DN08477A (OSRAM)
JO (1) JO3630B1 (OSRAM)
MA (1) MA37438A1 (OSRAM)
MX (1) MX358411B (OSRAM)
MY (1) MY175225A (OSRAM)
NZ (1) NZ700744A (OSRAM)
PH (1) PH12014502109A1 (OSRAM)
SG (2) SG10201607741RA (OSRAM)
TN (1) TN2014000387A1 (OSRAM)
TW (1) TWI649082B (OSRAM)
UA (1) UA117455C2 (OSRAM)
WO (1) WO2013142491A1 (OSRAM)
ZA (1) ZA201407551B (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
WO2016106357A1 (en) * 2014-12-23 2016-06-30 Millennnium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
EP3317427B1 (en) * 2015-07-02 2020-12-23 Millennium Pharmaceuticals, Inc. Biomarkers of response to selective inhibitors of aurora a kinase
CN114681455A (zh) * 2018-08-17 2022-07-01 深圳微芯生物科技股份有限公司 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
FR2450833A1 (fr) 1979-02-07 1980-10-03 Hoffmann La Roche Derives de benzazepine
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CN1084747C (zh) 1996-03-08 2002-05-15 曾尼卡有限公司 作为神经活性剂的吡咯并苯并氮杂䓬衍生物
JP2001507349A (ja) 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
CN1155599C (zh) 1997-09-29 2004-06-30 明治制果株式会社 三环三唑并苯并氮杂�衍生物、用于制备该衍生物的方法和抗变态反应剂
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
AU2001296871A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
BR0211729A (pt) 2001-08-09 2004-08-24 Actelion Pharmaceuticals Ltd Compostos, composições farmacêuticas, processo para fabricar compostos, uso de um ou mais compostos, e, processo para fabricar composições farmacêuticas
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
AU2005213472A1 (en) 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
ES2299080T3 (es) 2004-05-14 2008-05-16 Millennium Pharmaceuticals, Inc. Compuestos y metodos para inhibir la progresion mitotica mediante la inhibicion de quinasas aurora.
WO2006055831A2 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
US20100160324A1 (en) 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
SI1962830T1 (sl) 2005-12-23 2013-07-31 Glaxosmithkline Llc Azaindolni inhibitorji kinaz Aurora
JP2009523784A (ja) 2006-01-16 2009-06-25 ジュビラント・オルガノシス・リミテッド 酸不安定化合物の安定な医薬製剤およびその製造方法
AR059838A1 (es) 2006-03-14 2008-04-30 Ranbaxy Lab Ltd Formulaciones para dosis estabilizantes de estatina
DE102006012301A1 (de) 2006-03-15 2007-09-20 Cemag-Anlagenbau-Dessau Gmbh Herstellung von Zementklinker
EP2054413A2 (en) 2006-08-09 2009-05-06 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
BRPI0718100A2 (pt) 2006-10-31 2013-11-05 Achillion Pharmaceuticals Inc Composições farmacêuticas de elvucitabina
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
PE20081891A1 (es) 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
KR20160130519A (ko) 2008-06-26 2016-11-11 안테리오스, 인코퍼레이티드 경피 운반
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
US8653064B2 (en) 2010-02-19 2014-02-18 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors

Also Published As

Publication number Publication date
GEP20186900B (en) 2018-10-10
AU2013235275B2 (en) 2017-12-07
US20130303519A1 (en) 2013-11-14
ZA201407551B (en) 2019-01-30
TN2014000387A1 (en) 2015-12-21
JP2015510945A (ja) 2015-04-13
PH12014502109A1 (en) 2014-12-10
SG10201607741RA (en) 2016-11-29
HK1206253A1 (en) 2016-01-08
MA37438A1 (fr) 2016-05-31
IN2014DN08477A (OSRAM) 2015-05-08
US10213436B2 (en) 2019-02-26
CN104271129A (zh) 2015-01-07
MY175225A (en) 2020-06-16
EA201491727A1 (ru) 2015-01-30
JO3630B1 (ar) 2020-08-27
ES2746946T3 (es) 2020-03-09
TW201343169A (zh) 2013-11-01
IL234686A0 (en) 2014-11-30
EA036434B1 (ru) 2020-11-10
KR102128866B1 (ko) 2020-07-01
NZ700744A (en) 2016-09-30
IL234686B (en) 2020-01-30
SG11201405621UA (en) 2014-10-30
KR20140144215A (ko) 2014-12-18
WO2013142491A1 (en) 2013-09-26
MX358411B (es) 2018-08-20
AU2013235275A1 (en) 2014-10-23
TWI649082B (zh) 2019-02-01
EP2827855A1 (en) 2015-01-28
EP2827855B1 (en) 2019-06-26
MX2014011324A (es) 2014-12-05
US20160193224A1 (en) 2016-07-07
UA117455C2 (uk) 2018-08-10
CA2868024A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
Iglesias et al. Drug resistance in non-small cell lung cancer: a potential for NOTCH targeting?
Hoang et al. Oncogenic signaling of MEK5-ERK5
JP6263468B2 (ja) Ｍｅｋ阻害剤およびオーロラａキナーゼの選択的阻害剤の組み合わせ
KR20220030222A (ko) Tead 억제제 및 이의 용도
JP6757959B2 (ja) 抗がん剤
JP2016539156A (ja) オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
JP6373252B2 (ja) オーロラキナーゼ阻害薬を使用する癌の治療方法
JP2025519119A (ja) Ｍｅｋ阻害剤及びその使用
EP3212650B1 (en) Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents
WO2014177915A1 (en) Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
CA2782146A1 (en) Small pyrimidine derivatives and methods of use thereof
CN102105148B (zh) 包含aurora激酶抑制剂和抗肿瘤药的治疗组合
WO2022187849A1 (en) Salinomycin derivatives and uses thereof
CN102105147B (zh) 包含aurora激酶抑制剂和抗肿瘤药的治疗组合
HK1206253B (en) Combination of alisertib and paclitaxel for the treatment of cancer
WO2017015316A1 (en) Administration of aurora kinase inhibitor and chemotherapeutic agents
JP2014034534A (ja) ＨＳＰ９０阻害剤とｍＴＯＲ阻害剤の組み合わせ
JP2014091712A (ja) Ｈｓｐ９０阻害剤と抗腫瘍性タキサン化合物との組み合わせ
JP2014034535A (ja) Ｈｓｐ９０阻害剤とｖｅｇｆｒチロシンキナーゼ且つｐｄｇｆチロシンキナーゼ阻害剤の組み合わせ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180423

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180629

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180717

R150 Certificate of patent or registration of utility model

Ref document number: 6373252

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250